Molecular structure of BGJ398, CAS Number: 872511-34-7
BGJ398 (CAS 872511-34-7)
See product citations (4)
Alternate Names:
NVP-BGJ398
Application:
BGJ398 is a potent and selective inhibitor of Flg (FGFR-1), Bek (FGFR-2), FGFR-3 and FGFR-4
CAS Number:
872511-34-7
Molecular Weight:
560.48
Molecular Formula:
C26H31Cl2N7O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
BGJ398 is a potent and selective fibroblast growth factor receptor family inhibitor for Flg (FGFR-1), Bek (FGFR-2), FGFR-3 and FGFR-4. BGJ398 has undergone in vitro investigations utilizing cancer cell lines from diverse origins. The results of these studies have demonstrated the inhibitory effect of BGJ398 on the growth of specific cancer cell types when cultured. BGJ398 has exhibited the ability to trigger apoptosis, a process of programmed cell death, in select cancer cell populations.
BGJ398 (CAS 872511-34-7) References
- FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. | Göke, F., et al. 2015. Clin Cancer Res. 21: 4356-64. PMID: 26015511
- Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model. | Komla-Ebri, D., et al. 2016. J Clin Invest. 126: 1871-84. PMID: 27064282
- Selective FGFR inhibitor BGJ398 inhibits phosphorylation of AKT and STAT3 and induces cytotoxicity in sphere-cultured ovarian cancer cells. | Cha, HJ., et al. 2017. Int J Oncol. 50: 1279-1288. PMID: 28350116
- BGJ398 for FGFR-altered advanced cholangiocarcinoma. | Gilbert, JA. 2018. Lancet Oncol. 19: e16. PMID: 29233557
- Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis. | Sahores, A., et al. 2018. Curr Cancer Drug Targets. 18: 979-987. PMID: 29237381
- BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression. | Kim, SH., et al. 2018. Int J Mol Sci. 19: PMID: 30326563
- TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. | Goyal, L., et al. 2019. Cancer Discov. 9: 1064-1079. PMID: 31109923
- Tumor-Induced Osteomalacia. | Florenzano, P., et al. 2021. Calcif Tissue Int. 108: 128-142. PMID: 32504138
- Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma. | Deng, H., et al. 2020. Liver Cancer. 9: 338-357. PMID: 32647635
- Knockdown of Bcl-2-Associated Athanogene-3 Can Enhance the Efficacy of BGJ398 via Suppressing Migration and Inducing Apoptosis in Gastric Cancer. | Li, K., et al. 2021. Dig Dis Sci. 66: 3036-3044. PMID: 33089486
- Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures. | Kähkönen, TE., et al. 2021. Cell Oncol (Dordr). 44: 205-218. PMID: 33119860
- Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma. | Botrus, G., et al. 2021. Expert Opin Investig Drugs. 30: 309-316. PMID: 33307867
- FGF receptor inhibitor BGJ398 partially rescues osteoarthritis-like phenotype in older high molecular weight FGF2 transgenic mice via multiple mechanisms. | Hurley, MM., et al. 2022. Sci Rep. 12: 15968. PMID: 36153352
Inhibitor of:
Angiogenesis, Bek, bFGF, Cnpy1, E230008N13Rik, FGF-2, FGF-8F, FGF-BP3, FGFR, FGFR-3, FGFR-4, FGFR1OP2, FIBP, Fibroblast Growth Factor (FGF), FIGNL1, Flg, FRRS1, FRS3, and GFR-1.Activator of:
Bek, LOC646576, and PRAT4B_Cnpy4.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BGJ398, 5 mg | sc-364430 | 5 mg | $216.00 | |||
BGJ398, 10 mg | sc-364430A | 10 mg | $252.00 | |||
BGJ398, 50 mg | sc-364430B | 50 mg | $594.00 | |||
BGJ398, 100 mg | sc-364430C | 100 mg | $1009.00 |